WishBone Medical entered into a private label agreement with Bone Solutions for worldwide rights to distribute OsteoCrete® magnesium-based bone void filler in pediatric applications.
OsteoCrete is the first bone void filler in the U.S. to incorporate magnesium oxide to enhance bone development. It is 100% resorbable and also injectable, moldable and biocompatible, and cleared for use in a range of treatments such as complex sport-related injuries to all musculoskeletal extremities trauma cases. Bone Solutions has surpassed 600 cases implanting OsteoCrete (up from 500 in February 2019), and the company seeks to develop additional bioresorbable implants for further applications with the technology.
Bioresorbable implants are of particular benefit in pediatric applications. “This product is the holy grail for pediatric orthopedics, as the resorbable properties eliminate the need for secondary operations,” says WishBone Founder and CEO, Nick Deeter. “Kids already harbor a lot of anxieties around the idea of surgery. If we can save patients and their families the expense and worries of follow-up procedures, that alone is a big win.”
WishBone Medical entered into a private label agreement with Bone Solutions for worldwide rights to distribute OsteoCrete® magnesium-based bone void filler in pediatric applications.
OsteoCrete is the first bone void filler in the U.S. to incorporate magnesium oxide to enhance bone development. It is 100% resorbable and also injectable,...
WishBone Medical entered into a private label agreement with Bone Solutions for worldwide rights to distribute OsteoCrete® magnesium-based bone void filler in pediatric applications.
OsteoCrete is the first bone void filler in the U.S. to incorporate magnesium oxide to enhance bone development. It is 100% resorbable and also injectable, moldable and biocompatible, and cleared for use in a range of treatments such as complex sport-related injuries to all musculoskeletal extremities trauma cases. Bone Solutions has surpassed 600 cases implanting OsteoCrete (up from 500 in February 2019), and the company seeks to develop additional bioresorbable implants for further applications with the technology.
Bioresorbable implants are of particular benefit in pediatric applications. “This product is the holy grail for pediatric orthopedics, as the resorbable properties eliminate the need for secondary operations,” says WishBone Founder and CEO, Nick Deeter. “Kids already harbor a lot of anxieties around the idea of surgery. If we can save patients and their families the expense and worries of follow-up procedures, that alone is a big win.”
Copy to clipboard 
